drugset / Trial / NCT01994668

Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects

NCT01994668

Phase 1 Completed 8 enrolled Pfizer
RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of 2-mg lorazepam intravenous administration in healthy Japanese adult subjects.

Timeline

Start
2014-01
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 2 mg Intravenous

Indications

No indication recorded.